AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (original). A peptide having a sequence comprising or consisting of QPLALEGSLQK.

2 (currently amended). A peptide selected from the group consisting of GGGPGAGSLQPLALEGSLQK, GSLQPLALEGSLQKRGIV, and QPLALEGSLQKRGIVEQ.

3 (original). The peptide having the sequence GSLQPLALEGSLQKRGIV.

4 (currently amended). The peptide having the sequence GGGPGAGSLQPLALEGSLQKRGIVEQ.

5 (currently amended) A peptide according to ~~any of claims 1 to 4~~claim 1, in combination with one or more peptides having a sequence selected from LAKEWQALCAYQAEPNTCATAQGEGNIK, KLKVESSPSRSDYINASPIIEHDP, and SFYLKNVQTQETRTLTQFHF.

6 (currently amended). A peptide or peptide combination according to ~~any of the preceding claims~~claim 1, comprising a peptide or peptides differing from those

specified by up and including 4 amino acid alterations (substitution and/or deletion and/or insertion) or one which is extended from any one of the above-mentioned residues at the N-terminus or C-terminus or both with one or more non-wild-type amino acid sequences.

7 (currently amended). A peptide according to ~~any of claims 1-6~~ claim 1 in combination with either

a. IA-2 752-75

b. IA-2 853-72

c. IA-2 709-36

d. IA-2 752-75 and IA-2 853-72

e. IA-2 709-36 and IA-2 752-75

f. IA-2 709-36 and IA-2 853-72, or

g. IA-2 709-36 and IA-2 752-75 and IA-2 853-72

8 (currently amended). A pharmaceutical composition comprising a peptide or peptide combination according to ~~any of claims 1 to 7~~claim 1, for the therapy of Type 1 diabetes.

9 (original). A pharmaceutical composition according to claim 8, in which the peptide or each peptide is conjugated or otherwise combined with a tolerance-promoting adjuvant or tolerance promoting cells.

10 (currently amended). A diagnostic method or kit for diagnosis of, or determination of a predisposition to, Type 1 diabetes, comprising a peptide or peptide combination according to ~~any of the preceding claims~~claim 1.

11 (currently amended). A method of treatment or prevention of Type 1 diabetes, in which a peptide or combination of peptides according to ~~any of claims 1 to 7~~ claim 1 is administered by parenteral or oral or topical routes, including intradermal, subcutaneous or intravenous injection, or nasally or orally or epicutaneously.

12 (original). A method according to claim 11, in which the peptide or each peptide in a combination of peptides is administered in an amount of up to about 1mg or more per single dose.

13 (original). A method according to claim 12, in which the peptide or each peptide in a combination of peptides is administered in an amount of from about 0.5 to about 500 micrograms or more per single dose.

14 (original). A method according to claim 13, in which a single dose contains from 5 to 250 μg of the, or each, peptide e.g. 5, 50, or 250 μg.

15 (currently amended). A method according to ~~any of claims 10 to 14~~claim 10, in which the peptide or combination is administered in conjunction with a tolerance-promoting adjuvant or tolerance promoting cells.

16 (original). A method of measuring the state of immunological tolerance of a patient to beta cells which comprises the following steps:-

a. Extracting the patient's peripheral blood mononuclear cells

b. Culturing these cells with any of the peptides or peptide combinations above

c. Applying a cytokine ELISPOT analysis to the cultured cells in order to quantitate the cellular production of cytokines eg interferon-γ and interleukin- 10.

17 (original). A method according to claim 16, in which the patient's immunological tolerance to beta cells is demonstrated by the presence of an increased number of interleukin-10 producing cells and a reduced number of interferon-γ producing cells.